Drugs / Pridopidine
Pridopidine
also known as
ACR16 · ACR-16 HYDROCHLORIDE · ACR16 HCL · ASP-2314 HCL · ASP-2314 HYDROCHLORIDE · FR-310826 · Huntexil · Pridopidina · +2 more
Small molecule targets DRD2
Trials 13 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03019289 | Apr 2017 → Feb 2018 | Huntington disease | Prilenia | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT03922711 | May 2019 → Jul 2020 | Parkinson disease | Prilenia | Terminated | No outcome recorded |
| Phase 2 | NCT02494778 | Sep 2015 → Jan 2018 | Huntington disease | Prilenia | Terminated | No outcome recorded |
| Phase 2 | NCT02006472 | Feb 2014 → Dec 2015 | Huntington disease | Prilenia | Completed | No outcome recorded |
| Phase 2 | NCT01306929 | Mar 2011 → Jan 2018 | Huntington disease | Prilenia | Completed | No outcome recorded |
| Phase 2 | NCT00724048 | Oct 2008 → Jul 2010 | Huntington disease | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT04615923 | Dec 2020 → Jul 2022 | amyotrophic lateral sclerosis | Merit E. Cudkowicz, MD | Completed | No outcome recorded |
| Phase 2/3 | NCT04297683 | Jun 2020 → Jul 2027 expected | amyotrophic lateral sclerosis | Merit E. Cudkowicz, MD | Recruiting | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT07609108 | Jun 2026 → Jun 2028 expected | Huntington disease | Prilenia | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07322003 | Feb 2026 → Mar 2028 expected | amyotrophic lateral sclerosis | Prilenia | Recruiting | No outcome recorded |
| Phase 3 | NCT04556656 | Oct 2020 → Mar 2023 | Huntington disease | Prilenia | Completed | No outcome recorded |
| Phase 3 | NCT00665223 | Apr 2008 → Jun 2010 | Huntington disease | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT06069934 | — | amyotrophic lateral sclerosis | Prilenia | No longer available | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2016-09-19 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Results from Exploratory 52-Week Phase 2 PRIDE-HD Study of Pridopidine in Huntington Disease tevapharm.com ↗ |
| 2014-04-24 | Teva Branded Pharmaceutical Products R&D, Inc. | Pride-HD Study Enrolling Patients Globally to Further Evaluate Pridopidine for the Symptomatic Treatment of Huntington’s Disease tevapharm.com ↗ |
| 2012-09-27 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Expands Central Nervous System (CNS) Development Pipeline with Acquisition of Huntexil® Development Program Rights from NeuroSearch A/S tevapharm.com ↗ |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pridopidine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02006472 ↗ |
| Known as | ACR-16 HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL596802 ↗ |
| Known as | ACR16 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00724048 ↗ |
| Known as | ACR16 HCL | ChEMBL registry synonym — accepted as the source's own label CHEMBL596802 ↗ |
| Known as | ASP-2314 HCL | ChEMBL registry synonym — accepted as the source's own label CHEMBL596802 ↗ |
| Known as | ASP-2314 HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL596802 ↗ |
| Known as | FR-310826 | ChEMBL registry synonym — accepted as the source's own label CHEMBL596802 ↗ |
| Known as | Huntexil | ChEMBL registry synonym — accepted as the source's own label CHEMBL596802 ↗ |
| Known as | Pridopidina | ChEMBL registry synonym — accepted as the source's own label CHEMBL596802 ↗ |
| Known as | PRIDOPIDINE HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL596802 ↗ |
| Known as | TV-7820 | “Pridopidine (TV-7820) capsules” NCT03019289 ↗ |
| Action | Activate | “Pridopidine's activation of S1R enhances cellular processes that are crucial for neuronal function and survival but are impaired in neurodegenerative diseases.” PMID 36811812 ↗ Feb 2023 |
| Modality | Small molecule | — CHEMBL596802 ↗ |
| Route | Oral | “Participants will receive ACR16 45 milligrams (mg) capsule orally once daily for the first 4 weeks.” NCT00665223 ↗ |
| Target | DRD2 | “Dopamine D2 receptor modulator” CHEMBL596802 ↗ |